Michal Bar‐Natan

2.8k total citations · 1 hit paper
41 papers, 1.3k citations indexed

About

Michal Bar‐Natan is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Michal Bar‐Natan has authored 41 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 16 papers in Genetics and 11 papers in Molecular Biology. Recurrent topics in Michal Bar‐Natan's work include Acute Myeloid Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers). Michal Bar‐Natan is often cited by papers focused on Acute Myeloid Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers). Michal Bar‐Natan collaborates with scholars based in United States, Israel and France. Michal Bar‐Natan's co-authors include Benjamin L. Ebert, David A. Frank, Richard M. Stone, Erik A. Nelson, James D. Griffin, David P. Steensma, Rafael Bejar, Kristen E. Stevenson, Petar Stojanov and Donna Neuberg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Michal Bar‐Natan

39 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

2014 405 citations Michal Bar‐Natan, Richard M. Stone et al. Blood profile →

Peers

Countries citing papers authored by Michal Bar‐Natan

Since Specialization

Citations

This map shows the geographic impact of Michal Bar‐Natan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michal Bar‐Natan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michal Bar‐Natan more than expected).

Fields of papers citing papers by Michal Bar‐Natan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michal Bar‐Natan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michal Bar‐Natan. The network helps show where Michal Bar‐Natan may publish in the future.

Co-authorship network of co-authors of Michal Bar‐Natan

This figure shows the co-authorship network connecting the top 25 collaborators of Michal Bar‐Natan. A scholar is included among the top collaborators of Michal Bar‐Natan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michal Bar‐Natan. Michal Bar‐Natan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Characterization of antecedent clonal hematopoiesis (CH) mutations in lymphoid and plasma cell neoplasms 2025 ·Blood ·Pinkal Desai, (unknown), Ying Li, Nuria Mencia-Trinchant, (unknown), (unknown), Ellen K. Ritchie, Michael S. Samuel, Jonathan Canaani, Michal Bar‐Natan, Olivier Elemento, Lesley Tinker, Wendy Cozen, Mónica L. Guzmán, Andrea Sboner, Gail J. Roboz	0
2	‘Secondary’ acute lymphoblastic/lymphocytic leukemia - done playing second fiddle? 2023 ·Blood Reviews ·(unknown), John Mascarenhas, Michal Bar‐Natan	5
3	P389: METHOTREXATE NEUROTOXICITY IN ADULT ALL 2023 ·HemaSphere ·(unknown), (unknown), Orrin Pail, (unknown), Marina Kremyanskaya, John Mascarenhas, Michal Bar‐Natan	1
4	ALL-625 Methotrexate Neurotoxicity in Adult Acute Lymphoblastic Leukemia 2023 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), (unknown), (unknown), Orrin Pail, Marina Kremyanskaya, John Mascarenhas, Michal Bar‐Natan	0
5	Array CGH + SNP in ALL Enhances Detection of Complex Cytogenetic Profiles and Suggests That PRSS1 Loss May Play a Role in Leukemogenesis 2023 ·Blood ·(unknown), (unknown), (unknown), Tianxiang Sheng, Dahniel Sastow, Jonathan Feld, Douglas Tremblay, Marina Kremyanskaya, John Mascarenhas, Vesna Najfeld, Michal Bar‐Natan	1
6	Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk 2022 ·Blood Research ·(unknown), (unknown), John Mascarenhas, Marina Kremyanskaya, Shyamala Navada, Michal Bar‐Natan, Sara Kim	4
7	Central Nervous System Specific Characteristics and Outcomes in Acute Myeloid Leukemia Patients with Neurologic Involvement 2022 ·Blood ·Dahniel Sastow, (unknown), (unknown), Jonathan Feld, Michal Bar‐Natan, Alla Keyzner, Lewis R. Silverman, Marina Kremyanskaya, John Mascarenhas, Douglas Tremblay	1
8	Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119 2022 ·Blood ·Michal Bar‐Natan, John Mascarenhas, Aaron T. Gerds, Ruben A. Mesa, Vikas Gupta, Marina Kremyanskaya, (unknown), Frank Fabris, Kathryn Johnson, (unknown), Heidi Kosiorek, Carolyn Mead‐Harvey, Amylou C. Dueck, Ronald Hoffman, Raajit K. Rampal	9
9	Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures 2021 ·Blood ·Alberto Herrera, Anthony Cheng, Eleni P. Mimitou, (unknown), (unknown), Michal Bar‐Natan, Adriana Heguy, Kelly V. Ruggles, José U. Scher, Kenneth B. Hymes, Jo‐Ann Latkowski, Niels Ødum, Marshall E. Kadin, Zhengqing Ouyang, Larisa J. Geskin, Peter Smibert, Terkild B. Buus, Sergei B. Koralov	45
10	Results of a Phase II Study of PD-1 Inhibition in Advanced Myeloproliferative Neoplasms 2020 ·Blood ·Gabriela Hobbs, Cansu Cimen Bozkus, Martha Wadleigh, Lonette Sandy, (unknown), Kathryn Johnson, (unknown), Julia Foster, (unknown), (unknown), Michal Bar‐Natan, Richard M. Stone, Erin Moshier, Camelia Iancu‐Rubin, John Mascarenhas	7
11	JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia 2019 ·Blood Reviews ·Sangeetha Venugopal, Michal Bar‐Natan, John Mascarenhas	44
12	Management of Intraoperative Coagulopathy 2018 ·Neurosurgery Clinics of North America ·Michal Bar‐Natan, Kenneth B. Hymes	5
13	Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1 2017 ·British Journal of Haematology ·Michal Bar‐Natan, Dina Stroopinsky, Katarina Luptakova, Maxwell Coll, Arie Apel, Hasan Rajabi, Athalia R. Pyzer, Kristen Palmer, Michaela R. Reagan, Myrna Nahas, Rebecca Karp Leaf, Salvia Jain, Jon Arnason, Irene M. Ghobrial, Kenneth C. Anderson, Donald Küfe, Jacalyn Rosenblatt, David Avigan	23
14	Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma 2015 ·Blood ·Salvia Jain, Dina Stroopinsky, Yin Li, Jacalyn Rosenblatt, Maroof Alam, Parul Bhargava, Rachael A. Clark, Thomas S. Kupper, Kristen Palmer, Maxwell Coll, Hasan Rajabi, Athalia R. Pyzer, Michal Bar‐Natan, Katarina Luptakova, Jon Arnason, Robin Joyce, Donald Küfe, David Avigan	28
15	Immunotherapy for multiple myeloma 2014 ·Expert Review of Hematology ·Jacalyn Rosenblatt, Michal Bar‐Natan, Nikhil C. Munshi, David Avigan	11
16	A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets 2013 ·Clinical Cancer Research ·Sophia Adamia, Benjamin Haibe‐Kains, Patrick M. Pilarski, Michal Bar‐Natan, Samuel Pevzner, Hervé Avet‐Loiseau, Laurence Lodé, Sigitas Verselis, Edward A. Fox, John P. Burke, Ilene Galinsky, Ibiayi Dagogo‐Jack, Martha Wadleigh, David P. Steensma, Gabriela Motyckova, Daniel J. DeAngelo, John Quackenbush, Richard M. Stone, James D. Griffin	79
17	Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target? 2013 ·Current Cancer Drug Targets ·Sophia Adamia, Patrick M. Pilarski, Michal Bar‐Natan, Richard M. Stone, James D. Griffin	11
18	STAT signaling in the pathogenesis and treatment of myeloid malignancies 2012 ·PubMed ·Michal Bar‐Natan, Erik A. Nelson, Michael Xiang, David A. Frank	70
19	Early death in patients diagnosed with non-Hodgkin’s lymphoma 2012 ·Annals of Hematology ·Osnat Bairey, Michal Bar‐Natan, Ofer Shpilberg	14
20	The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations 2012 ·Genes & Cancer ·E Andrea Nelson, Sue Walker, Michael Xiang, Ellen Weisberg, Michal Bar‐Natan, R J Barrett, (unknown), Surender Kharbanda, Amanda L. Christie, (unknown), James D. Griffin, Richard M. Stone, Andrew L. Kung, David A. Frank	86

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact